{
  "created_at": "Thu Jun 24 20:22:31 +0000 2021",
  "id_str": "1407999930833289218",
  "full_text": "In April we wrote that phase-three trials of Sinovac yielded an efficacy rate barely above the 50% threshold set by the WHO for covid-19 vaccines, but very good protection against severe disease and death https://t.co/k1plWxugtT",
  "display_text_range": [
    0,
    228
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/k1plWxugtT",
        "expanded_url": "https://econ.st/3gPKKUX",
        "display_url": "econ.st/3gPKKUX",
        "indices": [
          205,
          228
        ]
      }
    ]
  },
  "user": {
    "name": "The Economist",
    "screen_name": "TheEconomist",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/879361767914262528/HdRauDM-_normal.jpg"
  },
  "retweet_count": 34,
  "favorite_count": 83,
  "possibly_sensitive": false,
  "original_created_at": "Thu Jun 24 09:51:57 +0000 2021"
}